Vigário Ana, Gonçalves João A, Costa Ana R, Pinheiro Guiomar, Reis Ernestina, Oliveira Júlio R
Internal Medicine Department.
Internal Medicine Department, Comissão de Controlo de Infeção e Resistência aos Antimicrobianos (CCIRA), Centro Hospitalar e Universitário do Porto, Porto, Protugal.
Porto Biomed J. 2020 Jun 4;5(3):e68. doi: 10.1097/j.pbj.0000000000000068. eCollection 2020 May-Jun.
The emergence of carbapenemase-producing Enterobacterales (CPE) represents a major public health threat. Our purpose was to evaluate a surveillance and cohorting program implemented in patients infected or carriers of CPE.
A prospective registry of CPE carriers or infected patients was analyzed from October 2015 until December 2017. All inpatients presenting with CPE were included in a hospital cohort with dedicated healthcare staff and contact precaution measures.
A total of 480 patients were identified, of which 15.8% (n = 76) were infected. Men comprised 56.7% of the cohort (n = 272) and 69.2% (n = 332) were elderly. About 46.3% (n = 222) had a previous hospital admission and 81.7% (n = 392) had at least 1 antibiotic course in the previous 90 days. There was a decline in infected patients in 2017. Periodic and admission screenings accounted for 63% and 74% of cases in 2016 and 2017, with increased detection rate comparing with contact/investigation screenings. In 2017, significantly fewer patients were identified outside the admission/point of prevalence screening ( = .009). In 2017 the proportion of invasive carbapenem-resistant amongst CPE in our center was below the national average (2016: 13.3% vs 5.2%; 2017: 6.6% vs 8.6%). A reduction of the consumption of carbapenems was also observed in 2017.
The implementation of the program has increased the number of patients identified by the preventive method and stabilized the emergence of new CPE cases. Furthermore, the program cohort compared well with the national picture, with a lower number of infected patients and a lower proportion of carbapenem-resistant in invasive specimens. These indicators reflect the added value of the CPE surveillance and cohorting program.
产碳青霉烯酶肠杆菌科细菌(CPE)的出现对公共卫生构成重大威胁。我们的目的是评估一项针对CPE感染患者或携带者实施的监测和队列研究计划。
分析了2015年10月至2017年12月期间CPE携带者或感染患者的前瞻性登记资料。所有出现CPE的住院患者均被纳入一个由专门医护人员负责并采取接触预防措施的医院队列。
共识别出480例患者,其中15.8%(n = 76)为感染患者。男性占队列的56.7%(n = 272),69.2%(n = 332)为老年人。约46.3%(n = 222)曾有过住院史,81.7%(n = 392)在过去90天内至少接受过1个疗程的抗生素治疗。2017年感染患者数量有所下降。2016年和2017年,定期筛查和入院筛查分别占病例的63%和74%,与接触/调查筛查相比,检测率有所提高。2017年,在入院/患病率筛查之外识别出的患者明显减少(P = 0.009)。2017年,我们中心CPE中侵袭性碳青霉烯耐药菌的比例低于全国平均水平(2016年:13.3%对5.2%;2017年:6.6%对8.6%)。2017年还观察到碳青霉烯类药物的消耗量有所减少。
该计划的实施增加了通过预防方法识别出的患者数量,并稳定了新CPE病例的出现。此外,该计划队列与全国情况相比良好,感染患者数量较少,侵袭性标本中碳青霉烯耐药菌的比例较低。这些指标反映了CPE监测和队列研究计划的附加价值。